Literature DB >> 43164

A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

J J McNeil, W J Louis.   

Abstract

1 This study was designed to compare in a double-blind randomized crossover trial, atenolol, labetalol, metoprolol and pindolol. Considerable differences in dose (atenolol 138 +/- 13 mg daily; labetalol 308 +/- 34 mg daily; metoprolol 234 +/- 22 mg daily; and pindolol 24 +/-2 mg daily were required to produce similar antihypertensive effects. 3 The overall incidence of side-effects was similar with atenolol, metoprolol and pindolol but was slightly less with labetalol. Sleep disturbances and abnormal dreaming patterns were most frequent with pindolol. 4 There was a significantly greater fall in pulse rate during atenolol and metoprolol treatment periods.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43164      PMCID: PMC1429742     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment.

Authors:  C Davidson; U Thadani; W Singleton; S H Taylor
Journal:  Br Med J       Date:  1976-07-03

2.  Experience with pindolol, a betareceptor blocker, in the treatment of hypertension.

Authors:  J H Atterhög; H Dunér; B Pernow
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

3.  How safe are beta-blocking drugs?

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Med J Aust       Date:  1977-09-03       Impact factor: 7.738

4.  The use of prindolol (Visken) in the treatment of hypertension.

Authors:  T O Morgan; W J Louis; J K Dawborn; A E Doyle
Journal:  Med J Aust       Date:  1972-08-05       Impact factor: 7.738

5.  Effect of bronchodilator drugs on arterial blood gas tensions in bronchial asthma.

Authors:  K N Palmer
Journal:  Postgrad Med J       Date:  1971-03       Impact factor: 2.401

6.  USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

Authors:  B N PRICHARD; P M GILLAM
Journal:  Br Med J       Date:  1964-09-19
  6 in total
  16 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant?

Authors:  D G McDevitt
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

3.  The influence of beta-adrenoceptor blockade on left ventricular function.

Authors:  B Hahn; B E Strauer
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 4.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 5.  Beta-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity.

Authors:  W J Louis; J J McNeil
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade.

Authors:  E D Cooke; S A Bowcock; A T Smith
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Atenolol versus pindolol: side-effects in hypertension.

Authors:  E C Foerster; P Greminger; W Siegenthaler; H Vetter; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  The effect of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on circadian heart rate.

Authors:  P Fitscha; B Tiso; W Meisner; D Spitzer
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

10.  Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

Authors:  L H Opie; D White; J Lee; W F Lubbe
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.